Pieris Pharmaceuticals, Palvella Therapeutics Agree to Merge; Pieris Shares Jump

MT Newswires Live07-24

Pieris Pharmaceuticals (PIRS) and Palvella Therapeutics said Wednesday they have agreed to merge in an all-stock transaction.

The combined entity will focus on developing and marketing Palvella's QTORIN rapamycin, for treating skin diseases. Upon completion, the merged entity will operate as Palvella Therapeutics and is expected to trade on Nasdaq, according to the joint statement.

As part of the planned merger, Palvella has obtained commitments from a group of healthcare-focused investors in an oversubscribed $78.9 million private financing, which is expected to provide cash runway into the second half of 2027, the companies said. The merged entity is anticipated to have around $80.5 million in cash and cash equivalents upon the completion of the deal and concurrent private financing.

The merger, along with private financing, is expected to close in Q4, subject to regulatory approvals and customary conditions, the companies said.

Pieris Shares rose more than 70% in recent trading.

Price: 13.51, Change: +5.57, Percent Change: +70.15

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2453588117?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-24 22:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453588117","market":"sg","top_or_hot":-1,"title":"Pieris Pharmaceuticals, Palvella Therapeutics Agree to Merge; Pieris Shares Jump","media":"MT Newswires Live","content":"<html><body><p> Pieris Pharmaceuticals (PIRS) and Palvella <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said Wednesday they have agreed to merge in an all-stock transaction.</p><p>The combined entity will focus on developing and marketing Palvella's QTORIN rapamycin, for treating skin diseases. Upon completion, the merged entity will operate as Palvella Therapeutics and is expected to trade on Nasdaq, according to the joint statement.</p><p>As part of the planned merger, Palvella has obtained commitments from a group of healthcare-focused investors in an oversubscribed $78.9 million private financing, which is expected to provide cash runway into the second half of 2027, the companies said. The merged entity is anticipated to have around $80.5 million in cash and cash equivalents upon the completion of the deal and concurrent private financing.</p><p>The merger, along with private financing, is expected to close in Q4, subject to regulatory approvals and customary conditions, the companies said.</p><p>Pieris Shares rose more than 70% in recent trading.</p><p>Price: 13.51, Change: +5.57, Percent Change: +70.15</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pieris Pharmaceuticals, Palvella Therapeutics Agree to Merge; Pieris Shares Jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPieris Pharmaceuticals, Palvella Therapeutics Agree to Merge; Pieris Shares Jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-24 22:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pieris Pharmaceuticals (PIRS) and Palvella Therapeutics said Wednesday they have agreed to merge in an all-stock transaction.The combined entity will focus on developing and marketing Palvella's ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2453588117","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453588117","pubTimestamp":1721833146,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pieris Pharmaceuticals  and Palvella Therapeutics said Wednesday they have agreed to merge in an all-stock transaction.The combined entity will focus on developing and marketing Palvella's QTORIN rapamycin, for treating skin diseases. Upon completion, the merged entity will operate as Palvella Therapeutics and is expected to trade on Nasdaq, according to the joint statement.As part of the planned merger, Palvella has obtained commitments from a group of healthcare-focused investors in an oversubscribed $78.9 million private financing, which is expected to provide cash runway into the second half of 2027, the companies said. The merged entity is anticipated to have around $80.5 million in cash and cash equivalents upon the completion of the deal and concurrent private financing.The merger, along with private financing, is expected to close in Q4, subject to regulatory approvals and customary conditions, the companies said.Pieris Shares rose more than 70% in recent trading.Price: 13.51, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4080":"零售业房地产投资信托","ADC":"艾格里房产","BK4231":"零售房地产信托","PIRS":"Pieris Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Pieris Pharmaceuticals和Palvella Therapeutics同意合并；Pieris股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"LENZ":1,"PIRS":1},"content_text":"Pieris Pharmaceuticals (PIRS) and Palvella Therapeutics said Wednesday they have agreed to merge in an all-stock transaction.The combined entity will focus on developing and marketing Palvella's QTORIN rapamycin, for treating skin diseases. Upon completion, the merged entity will operate as Palvella Therapeutics and is expected to trade on Nasdaq, according to the joint statement.As part of the planned merger, Palvella has obtained commitments from a group of healthcare-focused investors in an oversubscribed $78.9 million private financing, which is expected to provide cash runway into the second half of 2027, the companies said. The merged entity is anticipated to have around $80.5 million in cash and cash equivalents upon the completion of the deal and concurrent private financing.The merger, along with private financing, is expected to close in Q4, subject to regulatory approvals and customary conditions, the companies said.Pieris Shares rose more than 70% in recent trading.Price: 13.51, Change: +5.57, Percent Change: +70.15","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453588117"}